HEC921 / HEC Pharm - LARVOL DELTA

HEC-922:A CDH17-4-1BB bispecific antibody targeting CDH17 positive tumors shows potent anti-tumor activity (AACR 2026) - "Initial drug feasibility and toxicity studies results of HEC-922 were favorable. Overall result demonstrated that HEC- 922 is a promising candidate for CDH17 positive cancer immunotherapy.HEC-921, another bispecific antibody developed on the same 4-1BB platform with Ly6G6D as the targeted tumor antigen, has completed Dose Range Finding (DRF) study in cynomolgus monkeys, with a no-observed-adverse-effect level (NOAEL) of 100 mg/kg, validating the safety of the 4-1BB platform."

Bispecific • IO biomarker • Colorectal Cancer • Gastric Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor • CDH17 • LY6G6D

A novel Ly6G6D/4-1BB bispecific antibody targeting DNA mismatch repair proficient colorectal cancers shows potent antitumor activities (AACR 2025) - "Initial drug feasibility and toxicity studies results of HEC921 were favorable. Overall result demonstrated that HEC921 is a promising candidate for Ly6G6D positive cancer immunotherapy."

IO biomarker • Mismatch repair • pMMR • Colorectal Cancer • Oncology • Solid Tumor • IFNG • IL2 • IL4 • LY6G6D